Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
Camilla Certelli(Università Cattolica del Sacro Cuore), Valerio Gallotta(Università Cattolica del Sacro Cuore), Aniello Foresta(Università Cattolica del Sacro Cuore), Giovanni Scambia(Agostino Gemelli University Polyclinic), Virginia Vargiu(Agostino Gemelli University Polyclinic), Luca Palmieri(Università Cattolica del Sacro Cuore), Silvio Andrea Russo(Università Cattolica del Sacro Cuore), Francesco Santullo(Agostino Gemelli University Polyclinic), Anna Fagotti, Luigi Pedone Anchora(Agostino Gemelli University Polyclinic)
Cited by 9
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Outcome of Cesarean scar pregnancy managed expectantly: systematic review and meta‐analysis
|Ultrasound in Obstetrics and Gynecology|2017|299
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
|Annals of Oncology|2024|277
Uterine serous carcinoma
|Gynecologic Oncology|2021|158